Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…
LLY’s Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1…
Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
We just covered the Jim Cramer Stock Portfolio: Top 10 Stock Picks. Eli Lilly and Company (NYSE:LLY) ranks…
Pharma’s AI Investment Signals New Drug Discovery Paradigm
From improved molecular design to AI-driven automation, waves of AI tools promise to accelerate therapeutic development. Still, skeptics…
Warning issued to anyone who uses Mounjaro – check batch numbers now
A safety alert has been issued after falsified Mounjaro pens were found. A safety alert has been issued…
Urgent warning about contaminated weight loss injections from UK Government
‘Fake fat jab sellers’ warning from health minister who tells the Mirror dodgy weight loss injections can cause…
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of…
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1,…
Queer Eye’s Tan France helps unthread obesity bias as part of Zepbound’s ‘Changing the Thread Collection’
New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease For Tan France,…
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly’s global supply chain INDIANAPOLIS,…
Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with…
Lilly launches new “Brain Health Matters” campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain…